Morning

About Us

Ironshore Pharmaceuticals Inc. is a US-based pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers.

What We Do


Based in Morrisville, North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals Inc. was founded in 2015 and is a wholly owned subsidiary of Toronto-based Highland Therapeutics, Inc.

Ironshore Pharmaceuticals Inc.

Controlled Release

 
430 Davis Drive, Suite 250
Morrisville, NC 27560
United States

Controlled Release

 
2370 State Route 70 West, Suite 309
Cherry Hill, NJ 08002
United States

Leadership


Dave Lemus
Chief Executive Officer

Danny Villeneuve
Chief Commercial Officer

Dr. Randy Sallee
Chief Medical Officer

Lewis E. Warrington, MD
Vice President, Medical Affairs

Don Allen
Senior Vice President, Manufacturing, Quality & Supply

Nilay Patel
SVP General Counsel, Chief Compliance Officer

Colin Boatwright
Chief Information Officer

Dave Lemus

Dave Lemus is Chief Executive Officer and Chief Financial Officer of Ironshore Pharmaceuticals. In this role, Dave provides strategic leadership and direction across several functions within the Company including Commercial Sales & Marketing, Medical Affairs, Market Access, Finance, Information Technology, Legal, Supply Chain, and HR.

Dave has extensive international business experience spanning over 20 years in the Pharmaceutical and Biotechnology sectors. He has held several senior executive management roles including CEO, COO and CFO at multiple bio-pharmaceutical companies, as well as holding non-executive Board roles in private and publicly traded companies in both Europe and North America.

Dave holds an M.S. from the Massachusetts Institute of Technology and a B.S. from the University of Maryland College Park, and is a C.P.A. in Maryland.

Danny Villeneuve

Danny Villeneuve serves as Chief Commercial Officer of Ironshore Pharmaceuticals, responsible for leading the commercial team, including marketing, sales, sales support, sales training and associated capabilities.

Danny has more than 20 years of operational and commercial leadership experience in the biopharmaceutical industry, including 13 years where he was directly involved in the commercialization of multiple ADHD medications both in the US and global market. In addition to ADHD, Danny commercialized products in the CNS, GI, diabetes and obesity markets

Danny earned his Bachelor of Science in Medical Biology at Université du Québec in Canada.

Dr. Randy Sallee

Dr. Randy Sallee serves as the Company's Chief Medical Officer. Dr. Sallee has extensive research experience in both preclinical and clinical drug development. His administrative posts have included positions of Vice Chairman of the Department and Division Chief of Child Psychiatry at Cincinnati Children's Hospital Medical Center. As a leader in pediatric clinical pharmacology, Dr. Sallee founded the Pediatric Pharmacology Research Unit (PPRU) at Cincinnati Children's Hospital and is credited with supporting pediatric labeling for well over 50 marketed drugs in a wide range the therapeutic areas. Dr. Sallee has expertise in Orphan Drug Development, and has worked to bring new therapies to market to treat Prader Willi, Tourette Syndrome, Frontotemporal Dementia and Rett Syndrome.

Dr. Sallee is the author of over one hundred publications in refereed scientific journals whose research has been funded by the National Institutes of Health since 1990.

Dr. Sallee holds doctorates in pharmacology (University of Pittsburgh) and medicine (SIU School of Medicine) and is Board Certified in Psychiatry, Child Psychiatry and Clinical Pharmacology.

Lewis E. Warrington, MD

Lewis E. Warrington, MD, is Vice President and Head of Medical Affairs responsible for developing and managing medical strategy and supportive tactics for commercialized brands as well as all other Medical Affairs activities including Field Medical.

Lewis most recently served as the Medical Affairs Strategic Lead at Merck responsible for the development of medical strategy for CNS and immunologic products. Prior to his time at Merck, Lewis was VP and Head of the CNS Medical Unit at Novartis with responsibility for various CNS products in ADHD, schizophrenia, and Alzheimer’s Disease. Before joining Novartis, Lewis was a Senior Medical Director in Medical Affairs at Sanofi responsible for commercialized and pipeline insomnia and depression products. Prior to Sanofi, Lewis began his pharmaceutical career as a Medical Director at Pfizer working in the schizophrenia disease area.

Lewis earned his medical degree from East Carolina University School of Medicine. He completed residency training in General Adult Psychiatry at the University of Virginia and fellowship training in Child and Adolescent Psychiatry at the University of Florida. He also completed a Postdoctoral Fellowship in Neuropsychopharmacology at Mayo Clinic.

Don Allen

Don Allen is a seasoned executive within the pharmaceutical industry who has led manufacturing and supply chain operations across a variety of organizations and technologies. He has 35 years of plant operations and engineering experience including areas of API processing, small volume parental, solid and semi-solid dosage form manufacturing and as well as other specialty dosage form manufacturing including medicated gum, aerosol and transdermal patch manufacturing.

Don has led organizations at several brand, generic and specialty pharmaceutical companies across multiple manufacturing sites. He had responsibility for implementation of ERP systems across several different platforms, and he has formed and led Operational Excellence programs with roots in continuous improvement and lean manufacturing.

Don has a B.S. in Chemical Engineering from Purdue University and an MBA from the Quinlan School of Business at Loyola University Chicago.

Nilay Patel

Nilay Patel is General Counsel and Chief Compliance Officer of Ironshore Pharmaceuticals.

Nilay has broad legal experience, from both private practice and as in-house counsel, supporting every stage of pharmaceutical development and commercialization, across several products and disease states.

Nilay holds a JD from Columbia Law School and a BS Biochemistry from NC State University. He is also a registered patent attorney.

Colin Boatwright

Colin is the Chief Information Officer of Ironshore Pharmaceuticals and is responsible for the IT strategy and ensuring all systems necessary to support operations and objectives are in place. His goal is to ensure technology adds the maximum value to help with the success of Ironshore's products.

Most recently, Colin was Vice President of TechOps at IQVIA where he ran the global technology aspects of the world's largest Contract Sales Organization. In that role he oversaw the development and implementation of operational systems for medical reps, medical science liaisons, nurse educators, and various roles support medical affairs. Additionally, he ran the organization’s patient support platforms. Prior to joining IQVIA, Colin held various C-level positions in several start-ups.

Colin earned his bachelor’s degree in mass communication from North Carolina State University.